Equillium (EQ) Research & Development (2018 - 2026)
Equillium (EQ) posted quarterly Research & Development of $3.0 million for Q1 2026, down 49.51% year-over-year from $5.9 million in Q1 2025, and up 94.73% quarter-over-quarter from $1.5 million in Q4 2025.
Equillium (EQ) Research & Development (2018 - 2026) Analysis & Trends
Equillium (EQ) has reported Research & Development for 9 consecutive years, with $3.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 49.51% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $14.5 million (down 56.76% YoY), while the FY2025 annual figure was $12.8 million, down 65.69% from the prior year.
- Research & Development advanced to $3.0 million in Q1 2026 per EQ's latest filing, from $1.5 million in the prior quarter.
- Across five years, Research & Development topped out at $10.8 million in Q2 2024 and bottomed at $400000.0 in Q3 2025.
- Historically, Research & Development has averaged $7.5 million across 5 years, with a median of $9.0 million in 2023.
- Annual changes were most pronounced in 2022 — Research & Development soared 83.04% — and 2025, when it plunged 95.82%.
- Equillium's Research & Development stood at $8.5 million in 2022, then grew by 7.73% to $9.2 million in 2023, then decreased by 20.35% to $7.3 million in 2024, then tumbled by 79.0% to $1.5 million in 2025, then surged by 94.73% to $3.0 million in 2026.
- Business Quant data shows EQ's Research & Development at $3.0 million in Q1 2026, $1.5 million in Q4 2025, and $400000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | 2.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.75 Mn |
| Mar 31, 2026 | 2.99 Mn |
| Dec 31, 2025 | 1.54 Mn |
| Sep 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 4.08 Mn |
| Mar 31, 2025 | 5.92 Mn |
| Dec 31, 2024 | 7.32 Mn |
| Sep 30, 2024 | 9.56 Mn |
| Jun 30, 2024 | 10.81 Mn |
| Mar 31, 2024 | 9.74 Mn |
| Dec 31, 2023 | 9.18 Mn |
| Sep 30, 2023 | 8.97 Mn |
| Jun 30, 2023 | 9.61 Mn |
| Mar 31, 2023 | 9.27 Mn |
| Dec 31, 2022 | 8.53 Mn |
| Sep 30, 2022 | 8.77 Mn |
| Jun 30, 2022 | 9.49 Mn |
| Mar 31, 2022 | 10.76 Mn |
| Dec 31, 2021 | 7.55 Mn |
| Sep 30, 2021 | 6.97 Mn |